The possible role of maintenance treatment for primary central nervous system lymphoma.

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. The elderly patients are also susceptible to the accelerated and detrimental cognitive side effects of whole-brain irradiation which is an alternative consolidation to high-dose chemotherapy. Maintenance therapy has been shown to be a promising strategy to prolong remission time in other hematopoietic malignancies. Herein, we discuss the place of maintenance treatment in PCNSL in view of perspective obtained from hematological malignancies and non-Hodgkin's lymphoma.

• Publication year

  2018

• Venue

  Blood reviews

• Publication date

  2018-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.blre.2018.03.003PMID 29551465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

  2017cited by this paper
• Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.

  2017cited by this paper
• Treatment of Elderly Patients With Acute Myeloid Leukemia

  2017cited by this paper
• Mature aggressive B-cell lymphoma across age groups – molecular advances and therapeutic implications

  2017cited by this paper
• Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma

  2017cited by this paper
• Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

  2017cited by this paper
• Ibrutinib: A Review in Chronic Lymphocytic Leukaemia

  2017cited by this paper
• Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

  2017cited by this paper
• Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies

  2017cited by this paper
• Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

  2017cited by this paper
• Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

  2017cited by this paper
• Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia

  2017cited by this paper
• Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series

  2017cited by this paper
• Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy

  2017cited by this paper
• Epidemiology for primary brain tumors: a nationwide population-based study

  2017cited by this paper
• Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

  2017cited by this paper
• Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

  2017cited by this paper
• EPID-09. INCREASED OVERALL SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OVER THE PAST 40 YEARS, EXCEPT IN THE ELDERLY

  2017cited by this paper
• Trends in primary central nervous system lymphoma incidence and survival in the U.S.

  2016cited by this paper
• Lenalidomide for the treatment of B-cell lymphoma

  2016cited by this paper
• Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Sequencing of chronic lymphocytic leukemia therapies.

  2016cited by this paper
• The role of whole brain radiation in primary CNS lymphoma.

  2016cited by this paper
• Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

  2016cited by this paper
• Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma

  2016cited by this paper
• High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

  2016cited by this paper
• A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma

  2016cited by this paper
• The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia

  2016cited by this paper
• Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma.

  2016cited by this paper
• Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

  2016cited by this paper
• Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

  2016cited by this paper
• Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

  2016cited by this paper
• High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

  2016cited by this paper
• A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

  2016cited by this paper
• Recommend maintenance therapy with lenalidomide in multiple myeloma.

  2016cited by this paper
• Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.

  2016cited by this paper
• ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

  2016cited by this paper
• Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

  2016cited by this paper
• Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders

  2016cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.

  2016cited by this paper
• Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes

  2015cited by this paper
• Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.

  2015cited by this paper
• Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia

  2015cited by this paper
• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

  2015cited by this paper
• B-cell receptor signaling in diffuse large B-cell lymphoma.

  2015cited by this paper
• Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group

  2015cited by this paper
• Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

  2015cited by this paper
• Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

  2015cited by this paper
• Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

  2015cited by this paper
• R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

  2015cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma

  2015cited by this paper
• Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.

  2015cited by this paper
• FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

  2015cited by this paper
• [Maintenance chemotherapy: futility or utility?].

  2015cited by this paper
• Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

  2015cited by this paper
• Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

  2015cited by this paper
• Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma

  2015cited by this paper
• First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

  2015cited by this paper
• Present and future treatment options for primary CNS lymphoma

  2015cited by this paper
• Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma

  2015cited by this paper
• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

  2015cited by this paper
• Metronomics: towards personalized chemotherapy?

  2014cited by this paper
• Drug Resistance in Cancer: An Overview

  2014cited by this paper
• Metronomic Chemotherapy in Hematological Malignancies

  2014cited by this paper
• Mutational analysis of primary central nervous system lymphoma

  2014cited by this paper
• Primary CNS Lymphoma

  2014cited by this paper
• Challenges in the treatment of elderly patients with primary central nervous system lymphoma.

  2014cited by this paper
• Progress in central nervous system lymphomas

  2014cited by this paper
• Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma

  2013cited by this paper
• How I treat CNS lymphomas.

  2013cited by this paper
• Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

  2013cited by this paper
• Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma

  2013cited by this paper
• Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

  2013cited by this paper
• Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.

  2013cited by this paper
• Chronic lymphocytic leukaemia – the role of the microenvironment pathogenesis and therapy

  2013cited by this paper
• Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience

  2012cited by this paper
• Cognitive functions in primary CNS lymphoma after single or combined modality regimens.

  2012cited by this paper
• Treatment of older patients with mantle-cell lymphoma.

  2012cited by this paper
• Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen

  2012cited by this paper
• Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).

  2012cited by this paper
• Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates

  2012cited by this paper
• Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma

  2011cited by this paper
• Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.

  2011cited by this paper
• Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

  2011cited by this paper
• Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.

  2011cited by this paper
• The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

  2011cited by this paper
• Review: Chemotherapy in newly diagnosed primary central nervous system lymphoma

  2010cited by this paper
• Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

  2010cited by this paper
• High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.

  2010cited by this paper
• Metronomic chemotherapy: new rationale for new directions

  2010cited by this paper
• Maintenance therapy for central nervous system lymphoma with rituximab

  2009cited by this paper
• Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

  2009cited by this paper
• Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma

  2009cited by this paper
• Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant

  2009cited by this paper

• Real-World Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma.

  2025cites this paper
• Both consolidation and maintenance treatment improve outcomes in primary central nervous system lymphoma: real-world evidence from a tertiary medical center

  2025cites this paper
• Radiomics model building from multiparametric MRI to predict Ki-67 expression in patients with primary central nervous system lymphomas: a multicenter study

  2025cites this paper
• Effective management of primary central nervous system posttransplant lymphoproliferative disorder in a kidney transplant recipient using surgery and rituximab, along with a literature review.

  2025cites this paper
• Programmed death inhibitors in CNS B-cell lymphoma: A literature review.

  2025cites this paper
• A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime

  2023cites this paper
• High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis

  2023cites this paper
• Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience

  2023cites this paper
• A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma

  2023cites this paper
• Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases

  2023cites this paper
• Central Nervous System Lymphoma: Novel Therapies

  2022cites this paper
• Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma

  2022cites this paper
• Treating primary lymphoma of the brain in AIDS patients via multifunctional oral nanoparticulate systems.

  2022cites this paper
• Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study

  2022cites this paper
• Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C

  2022cites this paper
• Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review)

  2021cites this paper
• Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.

  2021cites this paper
• Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity

  2021cites this paper
• Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort

  2021cites this paper
• Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom?

  2020cites this paper
• Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience

  2019cites this paper
• Primary CNS Lymphoma in the Elderly: The Challenge

  2019cites this paper
• Editorial: Hot Topics in Neuro-Oncology.

  2018cites this paper
• Improving outcomes in primary CNS lymphoma.

  2018cites this paper